BJ
BJGPY
Beijing Geekplus Technology Co., Ltd.$13.00 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $13.00
Since first trade
0.0%
from $13.00 · Feb 26
30 days
0.0%
from $13.00
Range since listing
$13.00–13.00
0% from high · low Feb 26
Avg volume 20D
0
Sep 29 spike 0
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
Signal stack
Where each data set points today.
- TrendRANGE
0% above its 50-day average. New closing low $13.00 on Oct 26.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
May 13, 2026 Clinical trial readout
Results Pending: SHR-2004 injection (Phase 3) — Completed 87d ago
Trial: A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Under
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Jun 9, 2026
Clinical Trial
Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer
Phase 2 · COMPLETED
Jun 8, 2026
Clinical Trial
A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)
Phase 2 · COMPLETED
May 13, 2026
Trial readout
Results Pending: SHR-2004 injection (Phase 3) — Completed 87d ago
Trial: A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty Sponsor: Beijing…
Apr 13, 2026
Trial readout
Results Pending: SHR-2004 injection (Phase 3) — Completed 57d ago
Trial: A Clinical Study of SHR-2004 Injection in Preventing Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty Sponsor: Beijing…
Apr 3, 2026
Clinical Trial
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
Phase 2 · COMPLETED